Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2025Clinical journal of oncology nursingOpen Access

Gene Therapy for Sickle Cell Disease: No Donor, No Problem

View Full Paper
Ask AI
Bookmark
Share

Authors

ESElana Smilow

Discussion

Loading...

Member takes

Overview

Autologous gene therapy offers curative intent for sickle cell disease patients, indicating new potential for care.

Key Points

  • Autologous gene therapy can now treat sickle cell disease without the need for a donor, expanding access significantly.
  • The FDA approved two types of gene therapy in December 2023, making treatment accessible to a wider patient population.
  • Managing care for patients undergoing gene therapy aligns closely with protocols for stem cell transplantation, requiring a skilled approach.
  • This novel gene therapy presents challenges for authorization and logistics, but offers transformative potential for patients.

Cite This Study

Elana Smilow (2025) studied this question.

synapsesocial.com/papers/68d5bd5ddc445aa9033afeadhttps://doi.org/10.1188/25.cjon.371-375
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hematopoietic stem cell therapy with gene modification to treat sickle cell disease2025
  2. 2Sickle cell disease: understanding pathophysiology, clinical features and advances in gene therapy approaches2025 · 14 citations
  3. 3Sickle Cell Disease: From Ancient Origins to Modern Breakthroughs in Gene Therapy2026
  4. 4Research on Treatment Strategies for the Treatment of Sicklemia Disease2025
  5. 5Advances in Sickle Cell Disease Treatment: A Comparative Review of Hematopoietic Stem Cell Transplantation and Gene Therapy (Casgevy and Lyfgenia).2025